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Summary Dengue diagnosis was one of the topics discussed at the symposium ‘The
Global Threat of Dengue — Desperately Seeking Solutions’ organized during the 10th
International Congress of Infectious Diseases held in Singapore in 2002. In this paper,
a review is presented focusing on the main advances, problems and challenges of
dengue diagnosis.
IgM capture ELISA, virus isolation in mosquito cell lines and live mosquitoes, dengue
speciﬁcmonoclonal antibodies and PCR have all representedmajor advances in dengue
diagnosis. However, an appropriate rapid, early and accessible diagnostic method
useful both for epidemiological surveillance and clinical diagnosis is still needed.
Also, tools that suggest a prognosis allowing for better management are also needed.
Finally, laboratory infrastructure, technical expertise and research capacity must be
improved in endemic countries in order to positively inﬂuence dengue surveillance,
clinical case management and the development of new approaches to dengue control.
© 2003 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
The very title of the symposium ‘The Global
Threat of Dengue-Desperately Seeking Solutions’
organized during the 10th International Congress of
Infectious Diseases in Singapore in 2002, highlights
the devastating impact of dengue fever (DF) and
dengue hemorrhagic fever/dengue shock syndrome
(DHF/DSS) as well our current inability to control
and prevent this disease.
Today, DF and DHF/DSS are considered the most
important arthropod-borne viral diseases in terms
of morbidity and mortality. More than 2.5 billion
people are at risk of infection and more than 100
countries have endemic dengue transmission. DHF
has been reported in 60 of them.1,2
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The burden of DF and DHF disease is not very well
documented; however in 1998 alone, more than 1.2
million cases were reported to the World Health
Organization, with south-east Asia, the western
Paciﬁc and more recently the Americas being the
most affected regions.2,3
The emergence and re-emergence of dengue can
be attributed to a number of underlying causes.
These include demographic and societal changes
such as population growth and unplanned urban-
ization; this can result in large, crowded human
populations living in urban centers with substan-
dard housing and inadequate water, sewage and
waste management systems. When these factors
are combined with increased movement of indi-
viduals from endemic areas, the deterioration of
effective mosquito control measures, and the lim-
ited ﬁnancial and human resources dedicated to
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the public health infrastructure, dengue can gain
a foothold within the population.4—6
Dengue virus infections may be asymptomatic, or
may lead to undifferentiated fever, DF or DHF/DSS.
The incubation period for dengue is four to six
days. Infants and young children usually develop
an undifferentiated febrile disease that can be
accompanied by a maculopapular rash. Older chil-
dren and adults may develop either a mild febrile
syndrome or the classical dengue fever, charac-
terized by fever, headache, myalgias, arthralgia
and rash. However, three or four days after the
onset of fever, and generally when the fever falls,
some patients present bleeding manifestations (at
least a positive tourniquet test), thrombocytopenia
and hemoconcentration. Hepatomegaly can also
be observed. Patients usually recover after ﬂuid
and electrolyte therapy. In severe cases, shock
is observed, characterized by signs of circulatory
failure (weak and rapid pulse, hypotension or nar-
rowing of the pulse pressure, cold and clammy skin
and restlessness). Shock is followed by death in
5—10% of cases if rehydration is insufﬁcient or de-
layed. Plasma leakage is the main characteristic of
DHF/DSS.7—10
Both syndromes, DF and DHF/DSS, are caused by
any of the four dengue serotypes that belong to the
family Flaviviridae. Dengue viruses are spherical,
lipid-enveloped viruses that contain a positive
strand RNA genome of approximately 10,200 nucl-
eotides coding for three structural proteins (capsid,
membrane and envelope) and seven non-
structural proteins (NS1, NS2a, NS2b, NS3, NS4a,
NS4b, NS5). The envelope protein (E) plays a key
role in several important processes including recep-
tor binding, blood cell hemagglutination, induction
of a protective immune response, membrane fusion
and virion assembly.11,12
Today, secondary infection by a different dengue
serotype is considered the most signiﬁcant individ-
ual risk factor for DHF/DSS.13—15 The presence of
circulating non-neutralizing, cross-reactive anti-
bodies in a previously immune individual allows for
enhancement of infection, favoring the increased
entrance of the virus into the target cell through
the cell Fc receptor.16 It seems that T cell responses
also play an important role in the pathogenesis of
the severe disease. Both CD4+ and CD8+ T cells
have been detected in naturally immunized people
and cytotoxic dengue-speciﬁc CD4+ T cell clones
have been shown to have both serotype-speciﬁc and
serotype-cross-reactive speciﬁcities. In this model,
previous infection with one dengue serotype re-
sults in the presence in the host of cross-reactive
antibodies and memory T cells. Once infected by a
different serotype, virus-antibody complexes lead
to complement activation and enhanced infec-
tion of monocytic cells. The targeting of dengue
virus-infected monocytic cells by T cells results in
the release of cytokines, lysis of cells, and the re-
lease of intracellular enzymes and activators, lead-
ing to subsequent plasma leakage and shock.17,18
Recently, Mongkolsapaya et al., have reported
the presence of many dengue-speciﬁc T cells of
low afﬁnity for the infecting virus and higher afﬁn-
ity for the others. They suggest that a profound
T cell activation and death may contribute to the
systemic disturbances observed during DHF. They
also propose that original antigenic sin in the T
cell responses may suppress or delay viral elimi-
nation.19
The pathogenesis of DHF/DSS is not very well
understood nor are the host conditions that favor
the severe disease; however, children, females,
individuals with chronic diseases such as asthma and
diabetes, and whites appear to be at greater risk.
Finally, recent reports argue the risk of DHF/DSS
is higher if the interval is longer between primary
and secondary dengue infection.20—23
Among the many topics covered in the symposium
were new developments and challenges in the area
of dengue diagnosis.
Applications and implications of dengue
diagnosis
Accurate and efﬁcient diagnosis of dengue is
important for clinical care, surveillance support,
pathogenesis studies, and vaccine research. Diag-
nosis is also important for case conﬁrmation (DF
or DHF/DSS), to differentiate dengue from other
diseases such as leptospirosis, rubella, and other
ﬂavivirus infections, and for the clinical man-
agement and evaluation of patients with severe
disease.24,25
In conjunction with clinical and epidemiological
surveillance, the early detection of dengue circu-
lation or an increase in dengue activity provides
to health authorities useful information on time,
location, virus serotype and disease severity.7 The
use of good dengue diagnostic tools is critical
for laboratory conﬁrmation of DHF/DSS, including
the number of case fatalities, determining which
strains are involved, and to derive estimates of
total incidence following epidemics.7,26—31
Finally, dengue diagnosis is of major impor-
tance for research into host, virus and vector
characteristics, for determining the epidemiologi-
cal conditions inﬂuencing the pathogenesis of the
disease, and for vaccine evaluation (phase 1—3
studies).32—36
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Current protocols for the diagnosis of
dengue infections
Dengue diagnosis can be performed through virus
isolation, genome and antigen detection and sero-
logical studies. Serology is currently the most
widely applied in routine diagnosis. Of course,
clinical, geographical, and epidemiological data
associated with the patient remain critical consid-
erations when evaluating a laboratory result.
Serological diagnosis
Dengue infection in a non-previously immune host
produces a primary response of antibodies char-
acterized by a slow and low titer antibody re-
sponse. IgM antibody is the ﬁrst immunoglobulin
isotype to appear. Anti-dengue IgG appears in a
low titer at the end of the ﬁrst week of disease
onset, and increases slowly. By contrast, during a
secondary infection (dengue infection in a previ-
ously dengue or ﬂavivirus immune host), antibody
titers rise extremely rapidly and antibody reacts
broadly with many ﬂaviviruses.37 High levels of IgG
are detectable even in the acute phase and they
rise dramatically over the following two weeks.
The kinetics of the IgM response are more varied,
appearing late during the febrile phase of illness,
often preceded by IgG. Some anti-dengue IgM false
negative reactions are observed in secondary in-
fections. According to Pan American Health Orga-
nization (PAHO) guidelines,7 by day ﬁve of illness,
80% of cases have detectable IgM antibody, and by
day six to ten, 93—99% of cases have detectable
IgM that may persist for over 90 days.
Anti-dengue IgM detection using enzyme-linked
immunosorbent assay (ELISA) represents one of
the most important advances and has become an
invaluable tool for routine dengue diagnosis. Specif-
ically, MAC-ELISA (IgM antibody capture ELISA) di-
agnosis is based on detecting dengue-speciﬁc IgM
Table 1 Several commercial kits available on the market for detecting anti-dengue antibodies.
Commercial kits Immunoglobulin
isotype detection
Format References
PanBio Dengue Duo IgM/IgG ELISA 48,50,52
PanBio Dengue rapid test IgM/IgG Immunochromatographic test 46,49,51,52
MRL Diagnostic Dengue IgM ELISA 49
Blot IgMTM, Diagnostic Biotechnology Ltd. IgM Immunoblot kit 47
Venture Technologies Dengue IgM and IgG
Dot Blot kits
IgM/IgG Immunoblot kit 50
Integrated Diagnostics IgM Dipstick 51
Dengue Duo Rapid Strip Test, PanBio IgM/IgG Immunochromatographic test 53
UMELISA Dengue IgM IgM Ultramicro-ELISA 41
antibodies in the test serum by capturing them us-
ing anti-human IgM antibody previously bound on a
solid phase.37—39 In general, 10% false negative and
1.7% false positive reactions have been observed.
Different formats such as capture ELISA, capture
ultramicroELISA, dot-ELISA, AuBioDOT IgM capture
and dipstick have been developed.37,40—43 Serum,
blood on ﬁlter paper,7,44,45 and more recently saliva
are useful for IgM detection if samples are taken
within the appropriate time frame (after ﬁve days
of onset of fever). Different commercial kits46—53
for anti-dengue IgM and IgG detection are available,
with variable ﬁgures of sensitivity and speciﬁcity
(see Table 1).
In a suspected case of dengue, the presence of
anti-dengue IgM antibody suggests recent infection.
IgM detection is not useful for dengue serotype
determination due to the cross-reactivity of the an-
tibody observed even during primary infection. In
a series of serum samples of dengue patients from
Nicaragua, Panama and Costa Rica, a serotype-
speciﬁc IgM response was observed in only 15%
and 16% of DF and DHF cases respectively, and in
17% and 14% of the primary and secondary cases
(Guzman MG, unpublished data). Dengue IgM anti-
bodies also cross-react to some extent with other
ﬂaviviruses such as Japanese encephalitis and St.
Louis encephalitis and yellow fever.54,55
In an attempt to quantify IgM antibodies to
arboviruses of medical importance from three virus
families (Togaviridae, Flaviviridae and Bunyaviri-
dae), some investigators have used a standard-
ized combined MAC-ELISA using prototype viruses,
well-characterized human sera, and broadly
group-reactive monoclonal antibody conjugates.
This system has resulted in a good approach for
rapid screening of human serum samples for various
arboviruses.56
Clinically, diagnostic seroconversion is deﬁned as
a fourfold rise (or fall) in antibodies in paired sera
by hemagglutination inhibition (HI), complement
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ﬁxation (CF), plaque reduction neutralization
technique (PRNT) or ELISA.7,24,25,57,58 Due to the
presence of cross-reactive antigens shared by ﬂa-
viviruses, speciﬁc diagnosis is not possible in most
cases. When a serological speciﬁc diagnosis is re-
quired, PRNT is used, as this assay is the most
speciﬁc serological tool for the determination of
dengue antibodies.59
In order to determine the presence and quantity
of dengue-neutralizing antibodies, several proto-
cols have been developed; Vero and BHK21 cell lines
and carboxymethyl cellulose (CMC) and agarose
are frequently used, while some investigators use
peroxidase-antiperoxidase (PAP) staining.60—64 Cur-
rently, few laboratories use PRNT in their studies.
In order to implement PRNT, Shu et al. in
2002 standardized an NS1 serotype-speciﬁc indi-
rect ELISA to differentiate primary and secondary
dengue virus infections and obtained a good cor-
relation between anti-NS1 serotype-speciﬁc IgG
(determined by ELISA) and PRNT results.65,66 In
contrast, Cardosa et al., 2002, demonstrated that
the IgG response against premembrane protein
was speciﬁc to ﬂavivirus. No cross-reaction was
observed when sera were tested from individuals
infected with dengue virus or Japanese encephali-
tis virus. These authors recommended the use
of premembrane protein for seroepidemiological
studies.67
HI is the accepted serological technique68 how-
ever, as it is time consuming, ELISA has become
the most frequently used technique for serological
studies.
ELISA for anti-dengue IgG detection is currently
widely used for classifying cases based on the kind
of infection, primary or secondary. Some protocols
use serum dilutions to titer anti-dengue IgG. In
others, a ratio of IgM/IgG higher than 1.78 is con-
sidered a marker of primary infection, and less is
considered a marker of secondary infection.38,69—73
Relatively recently, some investigators have
demonstrated the usefulness of anti-dengue IgA de-
tection as an indicator of recent infection. Talarmin
et al. determined the presence of anti-dengue
IgM and IgA antibodies in 178 sera from patients
with DF.74 Figures of 100% sensitivity and speci-
ﬁcity were obtained. IgA antibodies were detected
at day six following the onset of fever until day
25. On average, IgM antibodies were detected at
day 3.8 and IgA at day 4.6. On the other hand,
Groen et al.75 also suggest the diagnostic value of
IgA serum detection using an immunoﬂuorescence
assay (IFA); however, a higher percentage of IgA
detection was observed in acute serum samples
from secondary cases (62%) when compared to pri-
mary cases (17%). Similar results were obtained
by Balmaseda et al. when they applied an ELISA
to the detection of anti-dengue IgA in sera.76 On
the other hand, Koraka et al. observed signiﬁcantly
higher levels of dengue virus-speciﬁc IgE in sera
of DHF/DSS, than in DF cases and non-dengue pa-
tients. The measurement of these antibodies is
proposed as a prognostic marker.77
Virus detection
Dengue viremia is short, is usually observed two to
three days before the onset of fever and lasts four
to ﬁve days later. Therefore, samples for virus iso-
lation must be taken in the ﬁrst four to ﬁve days of
the disease.
Serum is the sample of choice for routine diagno-
sis, however dengue virus can also be detected in
plasma, leukocytes and in tissues obtained at au-
topsy such as liver, spleen, lymph nodes, lung and
thymus.25,78—81 Because dengue virus is heat-labile,
appropriate handling of the specimens and prompt
delivery to the laboratory is required for successful
virus isolation. For short-term storage, specimens
may be kept at 4 ◦C, however for longer storage low
temperatures are recommended (−70 ◦C).
Mosquito inoculation is the most sensitive system
for dengue virus isolation and both adult and larval
mosquitoes can be used. Generally, Toxorhynchites
mosquitoes are preferable because of their large
size and because they are not haematophagous.
Adult male Aedes aegypti and Aedes albopictus
mosquitoes are also useful for virus isolation.82—86
Mosquito inoculation for dengue detection is also
useful in the quality control of vaccines. Jirakan-
janakit et al. inoculated Toxorhynchites splendens
with a tetravalent live attenuated dengue vaccine
and demonstrated that no interference between
serotypes occurred in infected mosquitoes.87
Because of the technical skill and special con-
tainment required for direct mosquito inoculation,
cell culture is preferable for routine diagnosis, de-
spite the greater sensitivity of methods employing
mosquitoes. It was clear from the ﬁrst reports of
their use that mosquito cell cultures were ideal for
dengue virus isolation. Different cell lines and cell
clones have been studied, however a cell line cul-
tured from Aedes albopictus (C6/36) has become
the host cell of choice for routine dengue virus iso-
lation, although the Aedes pseudoscutellaris cell
line AP61 has also been successfully used.88—96
Rodriguez et al.97 used a rapid centrifugation
technique to isolate the dengue virus cultured in
C6/36 cells and obtained 16.6% more isolates than
with the conventional method. Of even more im-
portance, this method was useful for isolating the
virus from tissue samples derived from fatal cases
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of dengue.79 These authors reported the recov-
ery of 42.8% of viral isolations from these tissue
samples.
Mammalian cell cultures such as Vero cells, LL-
CMK2 cells and others have also been employedwith
less efﬁciency.24,25,98
The oldest and least sensitive method for iso-
lating the virus is through the intracerebral inoc-
ulation of suckling mice—this is only used when
no other methods are available. Although many
animals develop symptoms or signs indicating en-
cephalitis, a large number of animals exhibit no
signs of illness.99,100 In terms of virus isolation,
the use of mosquito cell lines represents the most
important contribution to dengue diagnosis.
Virus identiﬁcation is generally accomplished us-
ing immunoﬂuorescence techniques with serotype-
speciﬁc monoclonal anti-dengue antibodies on
mosquito head squash, infected cells or brain tis-
sues from mice. Speciﬁc monoclonal antibodies
available at the American Type Culture Collection
and at World Health Organization Collaborating
Centers have simpliﬁed the identiﬁcation of these
viruses. In general, samples are ﬁrst tested by IFA
using a polyclonal antibody and those positives
are then re-tested with the four serotype-speciﬁc
monoclonal antibodies.101—104 Some strains are not
easily identiﬁed because of low virus concentra-
tion, and so some investigators have recommended
one or two passages through a cell culture system
in order to increase the viral concentration.104
Flow cytometry has recently been reported as a
useful method for dengue 1 identiﬁcation. It allows
the virus to be identiﬁed ten hours earlier than
an IFA where anti-NS1 monoclonal antibodies are
used.105
Antigen detection
IFA and radioimmunoassay (RIA) have detected
dengue viral antigens, however, the low sensitivity
of these tests has not allowed their application in
routine diagnostic purposes.80,106
In recent years, some sensitive systems have been
standardized in a typical ELISA format. In 1995, Ma-
lergue and Chungue applied a streptavidin-biotin
ampliﬁed ﬂuorogenic ELISA to the detection and
identiﬁcation of the dengue 3 antigen in serum.
This ELISA showed a sensitivity of 90% and speci-
ﬁcity of 98% when compared to virus isolation.107
Later, Kittigul et al. demonstrated that the dengue
antigen could be detected at a higher frequency in
peripheral blood mononuclear cells (PBMC) com-
pared to sera (53.8% as opposed to 18.9%). These
investigators also made use of a biotin-streptavidin
ELISA.108 More recently, attention has been focused
on NS1 antigen detection. Young and co-workers
standardized a capture NS1 ELISA and demon-
strated the presence of high levels of NS1 in the
acute phase serum of patients suffering from sec-
ondary infection. They suggested that NS1 antigen
detection could be useful for early diagnosis and
also as a marker of viremia.109 Similar results were
obtained by Alcon et al.110 Finally, Libraty et al.,
demonstrated the effectiveness of NS1 detection
as a predictor of DHF. NS1 levels in plasma corre-
lated with viremia levels and were higher in DHF
patients than in those with DF.111
A commercial kit based on two ELISAs for anti-
gen detection (blue kit) and identiﬁcation (red kit)
has also been recently produced. According to the
manufacturer, the sensitivity and speciﬁcity is 84%
and 89% for the blue kit and 91% and 93% for the red
kit (Globio Blue and Red Kit for antigen detection,
Globio Corp., Beverly, MA, USA).
Immunohistochemical techniques (using horse-
radish peroxidase or alkaline phosphatase labels)
have been shown to be useful for dengue anti-
gen detection in formalin-ﬁxed parafﬁn-embedded
tissue samples, although this technology is not
widely used for diagnosis in dengue endemic
countries.112—114
Genome detection
In recent years, PCR (polymerase chain reaction)
has become an important tool for the diagnosis of
dengue, for laboratory screening including ento-
mological surveillance, and for molecular epidemi-
ological studies.115 It has also proven useful as a
research tool in pathogenesis, antiviral drug and
vaccine studies.
DNA ampliﬁcation is preceded by a reverse trans-
cription reaction, producing cDNA from the target
RNA. Dengue RNA has been detected by PCR in se-
rum, plasma, infected cells, infected mosquito lar-
vae, mosquito pools, fresh and parafﬁn-embedded
tissues and formalin-ﬁxed tissue.29,30,115—117
Several PCR protocols have been developed.
Many of them apply a combination of four serotype-
speciﬁc oligonucleotide primer pairs in a sin-
gle reaction tube or use a universal dengue or
ﬂavivirus oligonucleotide primer pair followed
by a second ampliﬁcation with serotype-speciﬁc
oligonucleotides. These procedures also vary in the
genomic location of primers (E, NS1, E/NS1, prM/E,
NS5, NS5/3′), and in their speciﬁcity and sensitiv-
ity. Some protocols allow the detection of less than
50—100 dengue virus pfu.118—135 In the Americas,
the protocol developed by Lanciotti et al.122 has
been widely applied. These investigators designed
consensus primers to C/prM genes that amplify a
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511 bp product. In a second round of PCR, using
type-speciﬁc primers, DNA products of different
sizes are ampliﬁed, allowing the differentiation of
serotypes. Modiﬁcations to this protocol as well as
new protocols have also been used.120,125,130,134,135
When correctly applied, PCR has remarkable ad-
vantages as a tool for dengue diagnosis. The use of
PCR allows the detection of dengue in stored sam-
ples over long periods. Alvarez et al136 and later Sar-
iol et al29 demonstrated the dengue 2 virus in serum
and tissue autopsy samples fromDHF/DSS cases that
had been stored for more than 15 years. In addition,
they were able to classify the isolates by genomic
sequencing. Alternatively, different authors have
applied PCR to entomological surveillance. Chow
et al., 1998 and Kow et al. in 2001137,138 identiﬁed
dengue viruses in Aedes aegypti and Aedes albopic-
tus mosquito pools during a one-year surveillance
period in Singapore, allowing the application of vec-
tor control measures. Infected Aedes aegypti were
detected as early as six weeks before the recogni-
tion of a dengue outbreak in 1995 and 1996. These
authors recommend this method as an early warn-
ing monitoring system for dengue outbreaks.
PCR also allows the detection of concurrent in-
fections by multiple serotypes both in serum sam-
ples and in isolates from tissue culture or mosquito
inoculation.139—141 Laille et al., 1991, were able
to detect dual viremia by dengue 1 and dengue 3
in six DF patients during the 1989 New Caledonia
epidemic.139 Similarly, Loroño-Pino et al. were able
to show that 5.5% of the 292 samples they tested
showed evidence of concurrent dengue infection
with two or more serotypes.141
One of the most important applications of PCR
is the study of genetic strain variability in order to
identify the origin of epidemics and reveal mark-
ers of virulence. In conjunction with nucleotide
sequencing or restriction enzyme analysis, PCR
Table 2 Dengue genotype classiﬁcation according to different authors.
Group or subtype* References
Den 1 I French Polynesia/Fiji/Singapore/Indonesia/Nauru/New Caledonia/Tonga; II
Jamaica/French Guyana/New Caledonia/Brazil/Mexico/Aruba/Cuba/Peru/
Nicaragua/Thailand/Senegal/Malaysia/Puerto Rico; III Philippines/Thailand
146
Den 2 I Puerto Rico/Tahiti/Tonga/Colombia/Mexico/Venezuela/Trinidad; II
Taiwan/Philippines/New Guinea/Thailand; III Vietnam/Thailand/Jamaica; IV
Indonesia/Seychelles/Burkina Faso/Sri Lanka; V Ivory Coast/Burkina
Faso/Senegal
142,151
Den 3 I Philippines/Malaysia/Indonesia/Tahiti/Fiji; II Thailand; III Sri
Lanka/Samoa/India/Mozambique; IV Puerto Rico/Tahiti
145
Den 4 I Thailand/Philippines/Sri Lanka; II Tahiti/Puerto Rico/Brazil/New Caledonia/El
Salvador/Mexico/Dominica/Indonesia
147
* Genomic classiﬁcation in group or subtypes based on the nucleotide envelope study.
has allowed the classiﬁcation of dengue serotypes
into genotypes (Table 2).142—150 Rico-Hesse and
co-workers have developed a method to compare
dengue 2 genomes directly from patient plasma.
They found some amino acid and nucleotide
changes in the E protein gene as well as within the
untranslated region that may represent primary
determinants of DHF.151,152 In other studies, Kuno
et al. established the genetic relationship among
viruses of the Flavivirus genus. They proposed that
two branches of the virus evolved from the puta-
tive ancestor — non-vector and vector-borne virus
clusters — and from the latter cluster emerged
tick-borne and mosquito-borne viruses.153 Recent
reports suggest that intra-serotype recombination
of dengue virus occurs.154—157 The consequences of
these ﬁndings are not well deﬁned.
Finally, new PCR protocols and methodologies
have appeared that allow the rapid detection and
the quantiﬁcation of RNA. In 1999, Laue et al.
applied a fully automated ampliﬁcation proto-
col (based on the TaqMan principle) to measure
virus-speciﬁc DNA ampliﬁcation. This method
demonstrates a high speciﬁcity and sensitivity; it
eliminates the possibility of cross-contamination
and allows the determination of viral load.158 More
recently, Callahan et al., 2001, applied a TaqMan
RT/PCR assay to identify dengue serotypes and
groups, reporting a sensitivity of 92.5% and 98.5%
respectively, and a speciﬁcity of 100%, when com-
pared to viral isolation in C6/36 cells. Results were
obtained in less than two hours.159 Wu et al., 2001,
applied an isothermal nucleic acid sequence-based
ampliﬁcation (NASBA) assay to amplify the four
dengue serotypes using a set of universal primers
and serotype-speciﬁc capture probes for typing.
Nucleic acid was ampliﬁed without thermo cycling
and the product was detected by probe hybridiza-
tion using electrochemiluminescence. The assay
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showed a sensitivity of 98.5% and a speciﬁcity of
100% when compared to viral isolation from the
C6/36 cell line.160 More recently, a biosensor has
been added to the NASBA technique allowing the
rapid detection of dengue virus RNA in only 15
minutes.161 In an alternative approach, a ﬂuoro-
genic RT-PCR system was developed for the quan-
tiﬁcation and identiﬁcation of dengue viruses using
conserved and serotype-speciﬁc 3′-non-coding se-
quences. This system is able to detect 20—50 pfu/ml
of serum and showed a sensitivity of 92.8% and
speciﬁcity of 92.4% compared to virus isolation in
cell culture.162
Laboratory case classiﬁcation
The use of these diagnostic tests for dengue allows
the classiﬁcation of suspected clinical cases to be-
come probable or conﬁrmed cases. A positive IgM
serology, or a reciprocal HI antibody≥1280 or equiv-
alent IgG titer by ELISA are the criteria indicating
probable dengue infection. Dengue virus isolation,
dengue antigen demonstration or positive PCR, and
a fourfold or greater change in reciprocal IgG in
paired sera, are used to conﬁrm dengue infection.
Both probable and conﬁrmed cases are reportable
to health authorities.7
Dengue diagnosis, where we are today?
The main problems
IgM capture ELISA, virus isolation in mosquito cell
lines and live mosquitoes, dengue-speciﬁc mono-
clonal antibodies, and PCR have all representedma-
jor advances in dengue diagnosis. However, some
problems still warrant the timely development of
new solutions:
• Virus isolation is time consuming.
• PCR requires speciﬁc laboratory equipment and
facilities as well as extensive evaluation of the
different protocols under ﬁeld conditions.
• IgM antibody detection requires proper timing
and is confounded by false positive reactions and
the long persistence of IgM antibodies, commer-
cial kits still need to be critically evaluated, and
the costs and availability of these kits and other
reagents need to be addressed.
What is still needed for a better
diagnosis?
The continued development of inexpensive, sensi-
tive, speciﬁc and easy tests that allow for early
dengue diagnosis are still needed. Speciﬁcally, the
following aspects require the greatest attention: To
develop:
(a) Tests for early clinical diagnosis of individuals.
(b) Serological tests able to differentiate dengue
from other ﬂavivirus infections and even more
speciﬁcally to determine the infecting dengue
serotype.
(c) Easy and inexpensive protocols for genomic
characterization and viral load, including those
that can be applied in the ﬁeld.
(d) Modiﬁcations of existing protocols that simplify
specimen handling and transportation.
(e) Recombinant antigens as tools for test eval-
uation and to produce these for serological
tests.
(f) Tools that can suggest a prognosis, allowing for
better management of clinical follow up.
In addition to these speciﬁc items it is also
necessary to implement mechanisms for greater
reagent availability, for sharing standard reagents
(antigens, monoclonal antibodies, cell cultures,
positive and negative control sera), for the stan-
dardization of protocols in endemic regions, for im-
proving the quality and quantity of the proﬁciency
test, and for the enhanced exchange of informa-
tion and experiences between endemic areas in-
cluding the development of collaborative research
projects.163 The role ofWorld Health Organization’s
Collaborating Centers in all these aspects is
crucial.
There are some other problems and needs that
are not speciﬁcally related to technological devel-
opment. For instance, the laboratory infrastruc-
ture, technical expertise, and research capacity
is limited in many countries where dengue is en-
demic. These factors negatively inﬂuence dengue
surveillance, clinical management of cases, and
the development of new approaches to dengue
control. Although there are no published estimates
of the ﬁnancial support allocated for dengue ﬁeld
activities and research, it is not disputed that funds
are scarce. It is urgent that funds be mobilized
to increase basic public health capacity and im-
prove the infrastructure in endemic countries. This
could result in a decrease in dengue morbidity and
mortality, improved control, disease prevention
and improved knowledge of dengue and DHF/DSS.
The result would be an increase in investigations
directed towards diagnosis, vaccine development
and pathogenesis. Finally, we must advocate for
the urgent development of an appropriate rapid,
early and accessible diagnostic method for dengue
in order to save lives.
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